Francisco Silva - Oct 11, 2022 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
VP of Research and Development, Director
Signature
/s/ Francisco Silva
Stock symbol
BRTX
Transactions as of
Oct 11, 2022
Transactions value $
$2,973
Form type
4
Date filed
10/12/2022, 08:54 AM
Previous filing
Sep 9, 2022
Next filing
Oct 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BRTX Common Stock Purchase $2.97K +806 +0.49% $3.69 164K Oct 11, 2022 Direct F1, F2
holding BRTX Common Stock 12.1K Oct 11, 2022 IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BRTX Stock Option 1 Oct 11, 2022 Common Stock 1 $3,000.00 Direct F3
holding BRTX Stock Option 1 Oct 11, 2022 Common Stock 1 $3,000.00 Direct F3
holding BRTX Stock Option 3 Oct 11, 2022 Common Stock 3 $3,000.00 Direct F3
holding BRTX Stock Option 1 Oct 11, 2022 Common Stock 1 $3,000.00 Direct
holding BRTX Stock Option 9 Oct 11, 2022 Common Stock 9 $3,000.00 Direct F3
holding BRTX Stock Option 6 Oct 11, 2022 Common Stock 6 $3,000.00 Direct F3
holding BRTX Stock Option 15 Oct 11, 2022 Common Stock 15 $3,000.00 Direct F3
holding BRTX Stock Option 20 Oct 11, 2022 Common Stock 20 $3,000.00 Direct F3
holding BRTX Stock Option 25 Oct 11, 2022 Common Stock 25 $3,000.00 Direct F3
holding BRTX Stock Option 293K Oct 11, 2022 Common Stock 293K $13.50 Direct F4
holding BRTX Stock Option 42.1K Oct 11, 2022 Common Stock 42.1K $13.50 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $3.68 to $3.70 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.
F2 Includes 104,045 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on each of October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on each of November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
F3 The option is currently exercisable.
F4 The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F5 The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.